AGL stock holds as Agilon Health revenue and loss frame the 2026 outlook
Published on 07/21/2026 at 20:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AGL stock is tied to Agilon Health, Inc. (ISIN US00857U1079), whose latest reported figures still define the investment case: revenue of $1.52 billion in fiscal 2025, a net loss of $123.0 million in fiscal 2025, and cash and equivalents of $401.6 million at 31 December 2025. The company also reported adjusted EBITDA of -$20.4 million for fiscal 2025, according to its investor relations materials on Agilon Health investor relations.
Revenue and loss in 2025
The year-over-year comparison is direct: revenue rose from $1.49 billion in fiscal 2024 to $1.52 billion in fiscal 2025, while the net loss widened from $42.0 million to $123.0 million. That combination matters more than a single line item, because it shows modest top-line growth alongside a heavier bottom-line drag in the most recent annual period.
Adjusted EBITDA also moved in the wrong direction, from $58.1 million in fiscal 2024 to -$20.4 million in fiscal 2025. For investors, that swing is the clearest sign that margin execution, not just member growth, remains the central issue.
Liquidity still matters
Agilon Health ended fiscal 2025 with $401.6 million in cash and cash equivalents, compared with $484.5 million a year earlier. The decline was smaller than the loss headline might suggest, but it still leaves balance-sheet liquidity as a visible part of the story.
The same annual context helps explain why the market keeps paying attention to guidance, cost discipline, and medical-cost trends rather than revenue alone. A company that grows to $1.52 billion in annual revenue can still face pressure if profitability stays negative at -$123.0 million.
What the numbers say
The current investment discussion around AGL stock is therefore less about a single catalyst than about the gap between revenue scale and earnings quality. Fiscal 2025 showed that gap clearly: $1.52 billion in revenue, -$123.0 million in net income, and -$20.4 million in adjusted EBITDA, all from the company's own annual investor materials.
That mix also gives the stock a simple reference point for 2026: any improvement needs to show up first in margin stabilization, then in a smaller loss, and only later in a more durable profit profile. The latest annual numbers make that order of priorities hard to avoid.
Patient segments and care model
Agilon Health's business model centers on senior-focused primary care partnerships, so the key operating question is how efficiently the company converts membership scale into improved medical economics. The fiscal 2025 results show that revenue scale alone did not close the gap to profitability.
For a company built around value-based care, the product is not a consumer device or a single drug but the operating model itself: care coordination, partner practices, and utilization management. Those pieces matter because the financial outcome in fiscal 2025 was still negative even after revenue reached $1.52 billion.
AGL stock and the market view
Without a new quoted market price in the sourced material, the strongest market anchor remains the annual report backdrop itself: revenue, loss, EBITDA, and liquidity from fiscal 2025. Those are the numbers that frame how AGL stock is likely to be read until the next dated operating update.
Agilon Health, Inc. remains the company name used for this analysis, and the latest evidenced venue for its own reporting is its investor relations site. The fiscal 2025 figures provide the most current dated reference points in this article.
Agilon Health at a glance
- Company: Agilon Health, Inc.
- ISIN: US00857U1079
- Ticker: NYSE: AGL
- Trading venue: NYSE
- Sector / Industry: Health Care / Health Care Providers & Services
- Index membership: Not stated in the sourced material
- Next earnings date: Not officially scheduled in the sourced material
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
